Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Les indicacions geogràfiques protegeixen el nom d’un producte originari d’una zona geogràfica, a la qual li deu una determinada qualitat, reputació o una altra característica. Descobreix què són, en què consisteix el seu procediment de registre i quins beneficis atorguen.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
65
resultados
Última actualización
23/03/2026 [07:44:00]
Resumen de: WO2024235880A1
The invention relates to an in vitro method for diagnosing or predicting a neurodegenerative disease in a subject, said method comprising A/T/N classification in nasal secretion samples obtained from said subject. Said A/T/N classification subsequently may be used, but is not limited to, the diagnosis of Alzheimer's disease (AD), the diagnosis of SNAP or the exclusion of AD.
Resumen de: AU2026201500A1
Abstract Methods and compositions for preventing or treating cognitive decline associated with dementia and/or mild cognitive impairment and/or neurodegeneration using antibodies, peptides, fusion proteins, or genome editing systems that modulate HSPG/heparin binding affinities of ApoE.
Resumen de: CN121399472A
The present invention relates to a nasal fluid sample obtained from a subject, the nasal fluid sample comprising one or more marker protein amyloid beta (A beta), phosphorylated Tau (pTau) and/or total Tau (tTau). The invention further relates to a nasal fluid sample comprising one or more marker proteins A beta, pTau and/or tTau for use in a method for aiding in the diagnosis of a degenerative disease of the nervous system, and to the use of a nasal fluid sample comprising one or more marker proteins A beta, pTau and/or tTau for aiding in the diagnosis of a degenerative disease of the nervous system. The invention further relates to a method for aiding the diagnosis of a nervous system degenerative disease in a subject/individual.
Resumen de: WO2024235880A1
The invention relates to an in vitro method for diagnosing or predicting a neurodegenerative disease in a subject, said method comprising A/T/N classification in nasal secretion samples obtained from said subject. Said A/T/N classification subsequently may be used, but is not limited to, the diagnosis of Alzheimer's disease (AD), the diagnosis of SNAP or the exclusion of AD.
Resumen de: MX2022001817A
The methods disclosed herein employ unique combinations of processing steps that transform a blood or CSF sample into a sample suitable for quantifying MTBR tau species, as well as other tau species. The present disclosure also encompasses the use of MTBR tau species in blood or CSF to measure pathological features and/or clinical symptoms of 3R- and 4R- tauopathies in order to diagnose, stage, and/or choose treatments appropriate for a given disease stage, and modify a given treatment regimen.
Resumen de: AU2024366503A1
Methods, kits and compositions of detecting analytes, typically analytes relevant to neurodegenerative diseases such as neurofilament light chain, in a sample are described herein using chemiluminescent labels. Solid supports, reagents, and compounds for use in these methods are also described. Typically, the methods involve specific assay formats which provide the requisite high resolution for detecting low concentrations of analytes in samples and may be used in positions of the healthcare ecosystem close to the patient. These methods, systems, and apparatuses may afford early detection and prognosis of a wide variety of neurodegenerative diseases such as Alzheimer's disease and multiple sclerosis.
Resumen de: WO2026055173A1
The present invention provides a method for identifying a subject having a stabilized circulating peptide. The method comprises detecting the stabilized circulating peptide in a body fluid sample, for example, a serum or plasma sample, from the subject. The method may further comprise treating a neurodegenerative disease, or monitoring or adjusting a treatment of a neurodegenerative disease. Also provided is a kit. The kit comprises a binding protein that specifically binds a stabilized circulating peptide in a body fluid sample, for example, a serum or plasma sample, from a subject. The kit may further comprise an agent for detecting, treating or monitoring a neurodegenerative disease in the subject. The neurodegenerative disease may be Alzheimer disease.
Resumen de: WO2026051874A1
Provided are diagnostic and treatment methods,based on plasma protein markers for neurodegenerative diseases such as mild cognitive impairment (MCI) and Alzheimer's Disease (AD),as well as kits for diagnosing and/or treating these condition.Machine learning systems and methods for assessing the risk for a subject having a neurodegenerative disease based on measured protein marker levels are also provided.
Resumen de: US20260072043A1
The present disclosure provides methods for diagnosing or determining susceptibility to Alzheimer's Disease a subject by obtaining a biological sample from the subject; detecting one or more biomarkers in the biological sample selected from the group consisting of: inflammation biomarkers, oxidative stress biomarkers, insulin resistance biomarkers, and autophagy biomarkers; and diagnosing the subject with Alzheimer's Disease where one or more of the biomarkers is detected in the biological sample. Also provided are methods of treating a subject with Alzheimer's Disease comprising administering to the subject an effective amount of one or more agents for the treatment of inflammation, oxidative stress, insulin resistance, and/or autophagy.
Resumen de: US20260072040A1
The invention relates to methods and uses of cell free histone H3 isoforms H3.1, H13.2, H3t and/or H3.3 (or cell free nucleosomes containing said isoforms) of determining the origin of a cell free histone or cell free nucleosome in a body fluid sample as originating from a dividing or non-dividing cell.
Resumen de: CN121039498A
The present invention relates to a method for the in vitro diagnosis of a neurodegenerative disease in a human or animal individual in the early stage, comprising a step comprising the detection of the presence of at least one marker selected from the group consisting of derived forms of amyloid beta (A beta) peptides, the derivative forms are selected from oligomers of the peptide and pre-fibrotic and fibrotic aggregated forms of the peptide, and derivative forms of a phosphorylated tau protein, and the derivative forms are selected from over-phosphorylated forms of the protein, aggregated forms of the protein and modified phosphorylated tau proteins resulting from one or more post-translational modifications; the presence of a marker is detected in a fecal sample of the individual.
Resumen de: AU2024276342A1
Provided herein is a method for diagnosing and treating Alzheimer's disease comprising: (a) providing a biological sample obtained from the subject; (b) measuring concentration levels from the obtained sample, at least one, at least two, at least three, at least four or at least five Alzheimer's-related metabolites described herein and/or at least one, at least two, at least three, at least four or at least five Alzheimer's-related proteins described herein; (c) comparing the concentration levels of the Alzheimer's-related metabolites and/or proteins from the obtained sample to the concentration levels of corresponding reference Alzheimer's-related metabolites and/or proteins from an Alzheimer's- negative sample; (d) identifying the subject as having Alzheimer's if the concentration levels of the Alzheimer's-related metabolites and/or proteins from the obtained sample are different relative to the concentration levels of the reference Alzheimer's-related metabolites and/or proteins from the Alzheimer's-negative sample; and (e) treating or causing treatment of the subject.
Resumen de: AU2024322991A1
Herein is reported an antibody that binds to human A-beta protein, wherein the antibody comprises a heavy chain variable domain (VH) and a light chain variable domain comprising CDRs selected from (1) CDRs of SEQ ID NO: 85, 86, 87, 81, 82 and 83; or (2) CDRs of SEQ ID NO: 85, 89, 87, 81, 82 and 83; or (3) CDRs of SEQ 5 ID NO: 85, 86, 87, 81, 82 and 91; or (4) CDRs of SEQ ID NO: 85, 89, 87, 81, 82 and 91.
Resumen de: US20260061081A1
The present disclosure describes formulations, methods, and devices tor biomarker sampling and therapeutic delivery using magnetic formulations. When combined with the application of external magnetic fields, magnetic formulations move within the nasal cavity. Magnetic formulations provide benefits including the ability to: target or steer placement of the formulations via a magnetic field, enhance mixing of the formulation via a magnetic field, enhance biological material collection via antibody-coated magnetic beads, or enhance sample retrieval via a magnetic-tipped inserter. Example biological materials for collection include proteins, enzymes, neural stem cells, and other biomarkers.
Resumen de: AU2024345495A1
The disclosure pertains to treating a cognitive impairment, for example, an aging-associated cognitive impairment. In certain aspects, the disclosure describes methods of assaying a sample obtained from a subject having or suspected of having a cognitive impairment for one or more proteins selected from: DLL1, VNN2, VAV3, and SUMF1. In certain embodiments, the cognitive impairment is caused by a neurodegenerative disease, such as Alzheimer's disease. The methods further comprise identifying a subject as likely or not likely to respond positively to the plasma exchange therapy. In even further aspects, the disclosure describes methods for treating a cognitive impairment in the subject by a plasma exchange therapy, wherein based on the specific protein expression data, the subject is identified as likely or not likely to respond positively to the plasma exchange therapy. The plasma exchange therapy can be full and/or low volume plasma exchange. Also provided are kits suitable for performing the methods disclosed herein.
Resumen de: AU2024322991A1
Herein is reported an antibody that binds to human A-beta protein, wherein the antibody comprises a heavy chain variable domain (VH) and a light chain variable domain comprising CDRs selected from (1) CDRs of SEQ ID NO: 85, 86, 87, 81, 82 and 83; or (2) CDRs of SEQ ID NO: 85, 89, 87, 81, 82 and 83; or (3) CDRs of SEQ 5 ID NO: 85, 86, 87, 81, 82 and 91; or (4) CDRs of SEQ ID NO: 85, 89, 87, 81, 82 and 91.
Resumen de: AU2024325238A1
Material compositions and/or methods useful for the prophylaxis and/or treatment of protein depletion (proteinopenia) are provided, including material compositions that retains native function of a peptide/protein while limiting and/or preventing amyloid formation and/or aggregation of said peptide/protein. Material compositions and formulations for enhancing peptide/protein solubility, stability, circulation time, receptor interaction, brain penetrance, CSF half-life, facilitating peptide/protein synthesis and purification are also provided.
Resumen de: JP2025137567A
To provide phospho-tau antibodies, and to provide methods of use thereof.SOLUTION: Provided herein are compositions and methods relating to improved assays for establishing Alzheimer's disease. Further provided herein are compositions and methods comprising improved antibodies for assays including immunoassays. Provided herein is a method for detecting phosphorylated tau in a sample from an individual comprising: performing an immunoassay on the sample using an antibody or antibody fragment comprising a variable domain, heavy chain region (VH) and a variable domain, light chain region (VL), the VH comprising an amino acid sequence at least about 90% identical to a sequence as set forth in any one of SEQ ID NOs: 30 to 34, and the VL comprising an amino acid sequence at least about 90% identical to a sequence as set forth in any one of SEQ ID NOs: 35 to 40.SELECTED DRAWING: None
Resumen de: WO2026044141A1
Provided are recombinant diagnostic and therapeutic molecules and methods for their use in detecting and targeting Bcl-2 family proteins and/or Bcl-2 binding partners that are expressed on the surface of a cell or extracellular vesicle (EV) associated with the cancer, disease, or other condition.
Resumen de: WO2026044151A1
Provided are recombinant diagnostic and therapeutic molecules and methods for their use in detecting and targeting Bcl-2 family proteins and/or Bcl-2 binding partners that are expressed on the surface of a cell or extracellular vesicle (EV) associated with the cancer, disease, or other condition.
Resumen de: WO2026044051A1
CD9 expressing microglia are observed in various human neurodegenerative diseases beyond traumatic brain injuries, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis. CD9 blocking and FcγRIII blocking methods can be widely used as an intervention strategy to prevent disease-associated cognitive impairment. Therefore, disclosed herein are methods for treating a traumatic brain injury in a subject in need thereof that involve the step of administering to the subject a therapeutically effective amount of a composition comprising an anti-CD9 or an anti FcγRIII blocking agent, such as a blocking antibody.
Resumen de: WO2024220662A2
This document relates to methods and materials for detecting the presence or absence of misfolded polypeptides in a sample. For example, a sample (e.g., a biological sample or an environmental sample) can be exposed to nanoparticles (e.g., nanoparticles having a size of no more than 2 μm (e.g., no more than 1 μm) such as silica nanoparticles (siNPs) having a size of no more than 2 μm (e.g., siNPs having a size of no more than 1 μm)) during a seeded amplification assay to accelerate the aggregation of misfolded polypeptides present in the sample into fibrils and/or polypeptide aggregates (e.g., globular polypeptide aggregates). In some cases, methods and materials provided herein can be used to determine if a mammal (e.g., a human) has a proteinopathy based, at least in part, in the presence or absence of misfolded polypeptides in a sample obtained from the mammal.
Resumen de: KR20260024607A
본 발명은 아밀로이드 베타(amyloid beta, Aβ)와 특이적으로 결합하는 클러스터린(clusterin) 펩타이드 및 이의 용도에 관한 것이다. 본 발명의 아밀로이드 베타(Aβ)의 특이적으로 결합하는 클러스터린 유래 폴리펩타이드를 이용하는 경우, 아밀로이드 베타의 섬유화 및 올리고머화를 방지할 수 있으므로, 아밀로이드 베타 관련 퇴행성 신경질환의 치료 및 예방에 사용할 수 있으며, 뿐만 아니라, 클러스터린 베타 서브유닛(clusterin-β subunit)은 아밀로이드 베타 관련 퇴행성 신경질환의 진단을 위한 바이오마커로서 활용될 수 있다.
Resumen de: AU2026200694A1
Methods of measuring the amount of singly- or multiply-phosphorylated p217+ tau protein in a sample are provided. Methods of detecting or diagnosing tauopathies, methods of determining the effectiveness of a treatment of a tauopathy, and methods of determining whether a subject is suitable for anti-p217+ tau antibody therapy are also provided. Also described are antibodies for use in the methods and kits comprising the antibodies. an a n
Nº publicación: US20260048090A1 19/02/2026
Solicitante:
UNIV DO MINHO [PT]
UNIV OF AMSTERDAM [NL]
UNIVERSIDADE DO MINHO,
UNIVERSITY OF AMSTERDAM
Resumen de: US20260048090A1
The present disclosure relates to an engineered M13 bacteriophage displaying amyloidogenic peptide motifs from amyloid beta 42 (Aβ42) at its surface. The present disclosure further relates to the use of the disclosed engineered M13 bacteriophage for detecting early species of Aβ, namely oligomeric and fibrillar Aβ, and preventing its aggregation promoting the inhibition of the progression of Alzheimer's disease and thus contributing to the treatment of this neurodegenerative disorder.
BOPI
Sede Electrónica
